Perrigo Co. PLC expects to offer Prevacid 24 HR in an orally disintegrating tablet following its purchase of the brand from GlaxoSmithKline PLC, its first deal since making a “nationally brand better” commitment.
For GSK, divesting US rights to Prevacid 24 HR leaves it with another proton pump inhibitor to treat for frequent...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?